Vir Biotechnology Inc reports results for the quarter ended March 31 - Earnings Summary
08/05/2025 06:47
Vir Biotechnology Inc VIR.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -48 cents. The mean expectation of seven analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from $-1.03 to -67 cents per share. Revenue fell 94.6% to $3.03 million from a year ago; analysts expected $8.59 million. Vir Biotechnology Inc's reported EPS for the quarter was a loss of 88 cents. The company reported a quarterly loss of $120.97 million. Vir Biotechnology Inc shares had fallen by 13.4% this quarter and lost 23.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 3.5% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Vir Biotechnology Inc is $20.00 This summary was machine generated from LSEG data May 8 at 05:47 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.84 | -0.88 | Missed |
| Dec. 31 2024 | -0.87 | -0.76 | Beat |
| Sep. 30 2024 | -1.05 | -1.56 | Missed |
| Jun. 30 2024 | -0.90 | -1.02 | Missed |
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO